Angiotensin III

A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%).

Also Known As:

Networked: 48 relevant articles (0 outcomes, 9 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Llorens-Cortes, Catherine: 7 articles (01/2020 - 04/2005)
2.	Marc, Yannick: 5 articles (01/2020 - 05/2008)
3.	Balavoine, Fabrice: 3 articles (01/2020 - 05/2008)
4.	Martínez-Martos, J M: 2 articles (01/2021 - 01/2013)
5.	Ramírez-Expósito, M J: 2 articles (01/2021 - 01/2013)
6.	Ahmad, Monir: 2 articles (01/2019 - 03/2013)
7.	Leenen, Frans H H: 2 articles (01/2019 - 03/2013)
8.	Martínez-Martos, José Manuel: 2 articles (01/2018 - 10/2011)
9.	Ramírez-Expósito, María Jesús: 2 articles (01/2018 - 10/2011)
10.	Roques, Bernard P: 2 articles (08/2012 - 04/2005)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2020 - "One of the major components of the brain renin-angiotensin system implicated in the development of hypertension is Ang III (angiotensin III). " 04/01/2005 - "Role of angiotensin III in hypertension." 08/01/1985 - "Hypertension during chronic peripheral and central infusion of angiotensin III." 01/01/2019 - "Angiotensin III/AT2 Receptor/NHE3 Signaling Pathway in the Proximal Tubules of the Kidney: A Novel Natriuretic and Antihypertensive Mechanism in Hypertension." 01/01/2012 - "Recent evidence points to important contributions by brain angiotensin III (AngIII) and aminopeptidases A (APA) and N (APN) in sustaining hypertension. "
2.	Hyperaldosteronism (Conn Syndrome) 08/01/1996 - "Aldosterone changes during angiotensin III and potassium infusions in patients with primary aldosteronism." 05/20/1988 - "[Studies on abnormalities of adrenal steroidogenesis in essential hypertension, primary aldosteronism and renovascular hypertension: responses of plasma steroids to angiotensin III]." 04/01/1979 - "This study describes the effects of [des-Aspartyl(1)]-angiotensin II ([des-Asp]-AII) on blood pressure and aldosterone production in patients with primary aldosteronism due to aldosterone-producing adrenal adenoma (APA) and idiopathic adrenal hyperplasia (IHA), and in normotensive control subjects. " 05/20/1988 - "Angiotensin III(A III), an analogue of angiotensin II, was administered to 17 normal volunteers (9 male and 8 female), 44 patients with essential hypertension (EH) (15 with high renin; HREH, 15 with normal renin; NREH and 14 with low renin; LREH), 8 patients with primary aldosteronism (5 with adrenal adenoma; APA and 3 with bilateral adrenocortical hyperplasia; IHA) and 5 patients with renovascular hypertension. "
3.	Essential Hypertension 05/20/1984 - "[Changes in responses of blood pressure and several hormones to infusions of angiotensin II and angiotensin III in patients with essential hypertension]." 05/20/1988 - "[Studies on abnormalities of adrenal steroidogenesis in essential hypertension, primary aldosteronism and renovascular hypertension: responses of plasma steroids to angiotensin III]." 01/01/2013 - "Regarding the RAS, APA is reduced while APN is increased, suggesting increased levels of angiotensin II and a facilitation of the conversion of angiotensin III in angiotensin IV. Thus, the changes in several RAS-regulating specific activities and other enzyme activities involved in the neuroendocrine modulation of gonad and stress-related functions are related to essential hypertension with minor gender differences. " 05/20/1988 - "Angiotensin III(A III), an analogue of angiotensin II, was administered to 17 normal volunteers (9 male and 8 female), 44 patients with essential hypertension (EH) (15 with high renin; HREH, 15 with normal renin; NREH and 14 with low renin; LREH), 8 patients with primary aldosteronism (5 with adrenal adenoma; APA and 3 with bilateral adrenocortical hyperplasia; IHA) and 5 patients with renovascular hypertension. " 05/20/1984 - "In this study, the effects of angiotensin II (A II, Asn-Arg-Val-Tyr-Val-His-Pro-Phe) and angiotensin III (A III, Arg-Val-Tyr-Ile-His-Pro-Phe) on blood pressure (B.P.), pulse rate, several hormones [plasma renin activity (PRA), plasma aldosterone (PA), ACTH, plasma cortisol (PC), urinary catecholamines and urinary aldosterone] and urinary electrolytes were investigated in 9 male patients with essential hypertension [mean age 36.2 +/- 4.1 (S.E.) years]. "
4.	Prostatic Neoplasms (Prostate Cancer) 10/01/2012 - "Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation." 11/01/2008 - "Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells." 11/01/2008 - "The aim of this study was to perform a comprehensive evaluation of angiotensin III (Ang-III) and related converting enzymes, aminopeptidase A (APA) and N (APN), in prostate cancer. "
5.	Obesity 03/01/2017 - "These findings improve our comprehension about obesity-related hypertension and suggest new tools for its treatment.NEW & NOTEWORTHY In this study, we reported an increased angiotensin III generation in the circulation of ob/ob mice caused by a high aminopeptidase A activity. " 06/20/2023 - "It raises the possibility that centrally acting amino peptidase A inhibitors (eg, firibastat), preventing the conversion of angiotensin II to angiotensin III in the brain, might be particularly useful in African Americans and patients with obesity. "

Related Drugs and Biologics

1.	Angiotensin II
2.	Glutamyl Aminopeptidase (Aspartyl Aminopeptidase)
3.	Enzymes
4.	Aldosterone
5.	Renin
6.	Peptides (Polypeptides)
7.	Steroids
8.	Hydrocortisone (Cortisol)
9.	Hormones (Hormone)
10.	Electrolytes

Related Therapies and Procedures

1.	Surgical Instruments (Clip)
2.	Therapeutics